MedTrace Logo

Comparative Effects of Pilates Breathing and Pursed Lip Breathing on Chest Expension and Peak Expiratory Flow Rate in Patients With Chronic Obstructive Lung Disease

NCT07177976 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 46

Last updated 2025-10-07

No results posted yet for this study

Summary

Chronic Obstructive Pulmonary Disease is a particular type of irreversible disease that may damage or obstruct airways and make it difficult to breath. This respiratiry condition may lead to shallow breathing.

Breathing exercisers help to manage hyperventilation often seen in COPD patients. To handle respiratory complications patients are advised to practice breathing techniques along with pharmacological management

Conditions

  • Pulmonary Disease, Chronic Obstructive (COPD)

Interventions

PROCEDURE

Pilates Breathing Technique along with standard pharmacological management

Patients in this group will receive pilates breathing technique along with pharmacological management. A total 3 weeks protocol will be followed in which 2 seesions per week will be supervised by physiotherapist and 5 days at home. Pilates breathing will be performed in sitting or supine position. The patient will place a hand over the Lower Posterior rib Cage and inhale through the nose. While breathing they will actively contract the Transverse Abdominis (TrA) as if preparing for punch or holding in urine and engaging the pelvic floor muscles.

PROCEDURE

Pursed-lip breathing along with pharmacological management

Patient in this group will receive pursed-lip breathing along with pharmacological management. A total 3 weeks protocol will be followed in which 2 sessions per week will be supervised by physiotherapist and 5 days at home. The patient will sit comfortably with straight back and relaxed shoulders. They will inhale slowly through the nose, with a deep relaxed breath, and then exhale slowly through the pursed lips, as if blowing out a candle. The exhalation should take 2-3 times longer than inhalation. This breathing cycle will be repeated with a focus on slow and relaxed breathing. Pharmacological management: Patient will receive medications as per prescribed by pulmonologist

Sponsors & Collaborators

  • Foundation University Islamabad

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-09-15
Primary Completion
2026-01-01
Completion
2026-02-01

Countries

  • Pakistan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07177976 on ClinicalTrials.gov